Ballot initiative is a crucial step towards safe, legal microdosing
Microdosing Collective, the nation's first non-profit dedicated to advancing the right to microdose, today announced its support for Question 4 on the Massachusetts ballot. This initiative, if passed, would legalize the use of certain natural psychedelic substances for adults 21 and older at licensed therapy centers and decriminalize possession of small amounts for personal use.
"Question 4 represents a significant stride towards recognizing the potential benefits of psychedelics, including microdosing," said Sam Chapman, Policy and Development Director at Microdosing Collective. "Microdosing provides a safe, regulated, and affordable opportunity for those seeking to improve their mental health and wellbeing, and we are incredibly excited that individuals in Massachusetts will have legal access to regulated and tested psilocybin microdoses with the passage of Question 4."
Question 4 would create a regulatory framework for the therapeutic use of natural psychedelics in Massachusetts, similar to measures passed in Oregon and Colorado. It would also allow for limited home cultivation, a provision that could potentially benefit those interested in microdosing.
Dr. Jacqueline Jacques ND, board member of the Institute of Natural Medicine, emphasized the potential health implications: "As a naturopathic doctor, I've seen growing interest in microdosing as a wellness tool. Question 4 could pave the way for more research into sub-perceptual doses, potentially leading to safer, more accessible options for those seeking alternative approaches to mental health and well-being."
The initiative aligns with Microdosing Collective's goal of establishing legal frameworks that differentiate between microdosing and higher, consciousness-altering doses of psychedelics. While Question 4 doesn't make this distinction explicitly, the organization views it as a stepping stone towards more refined policies.
Tracey Tee, founder of Moms on Mushrooms and advocate for microdosing, shared her perspective: "Many individuals, particularly mothers, are turning to microdosing as a way to manage stress and improve mental health. We are witnessing a mental health crisis among mothers with addiction, depression, and suicide rates rising exponentially. Question 4 could help destigmatize this practice and potentially lead to safer access for those who might benefit."
Microdosing Collective estimates that about 4 million people in the U.S. are actively microdosing, with the market valued at around $100 million. However, the lack of regulation poses risks, as highlighted by recent safety incidents involving uncontrolled psychedelic products.
"Question 4 is an opportunity for Massachusetts to lead in creating a regulated psychedelic community that prioritizes safety and efficacy," Chapman added. "It's a crucial step towards a future where microdosing can be explored openly and safely."
The organization calls on Massachusetts voters to support Question 4, viewing it as a catalyst for broader discussions on psychedelic policy reform. Microdosing Collective remains committed to advocating for policies that recognize the unique nature of microdosing and ensure safe, legal access for those who choose to explore this practice.
About Microdosing Collective
Microdosing Collective is the only non-profit educational organization in the United States dedicated to advancing the right to microdose. Founded in 2023, it focuses on establishing a legal framework for microdosing psychedelics, particularly psilocybin, as wellness supplements. The organization is committed to educating the public, supporting research, and advocating for policy changes to create a safer, more accessible microdosing landscape.
"Question 4 represents a significant stride towards recognizing the potential benefits of psychedelics, including microdosing," said Sam Chapman, Policy and Development Director at Microdosing Collective. "Microdosing provides a safe, regulated, and affordable opportunity for those seeking to improve their mental health and wellbeing, and we are incredibly excited that individuals in Massachusetts will have legal access to regulated and tested psilocybin microdoses with the passage of Question 4."
Question 4 would create a regulatory framework for the therapeutic use of natural psychedelics in Massachusetts, similar to measures passed in Oregon and Colorado. It would also allow for limited home cultivation, a provision that could potentially benefit those interested in microdosing.
Dr. Jacqueline Jacques ND, board member of the Institute of Natural Medicine, emphasized the potential health implications: "As a naturopathic doctor, I've seen growing interest in microdosing as a wellness tool. Question 4 could pave the way for more research into sub-perceptual doses, potentially leading to safer, more accessible options for those seeking alternative approaches to mental health and well-being."
The initiative aligns with Microdosing Collective's goal of establishing legal frameworks that differentiate between microdosing and higher, consciousness-altering doses of psychedelics. While Question 4 doesn't make this distinction explicitly, the organization views it as a stepping stone towards more refined policies.
Tracey Tee, founder of Moms on Mushrooms and advocate for microdosing, shared her perspective: "Many individuals, particularly mothers, are turning to microdosing as a way to manage stress and improve mental health. We are witnessing a mental health crisis among mothers with addiction, depression, and suicide rates rising exponentially. Question 4 could help destigmatize this practice and potentially lead to safer access for those who might benefit."
Microdosing Collective estimates that about 4 million people in the U.S. are actively microdosing, with the market valued at around $100 million. However, the lack of regulation poses risks, as highlighted by recent safety incidents involving uncontrolled psychedelic products.
"Question 4 is an opportunity for Massachusetts to lead in creating a regulated psychedelic community that prioritizes safety and efficacy," Chapman added. "It's a crucial step towards a future where microdosing can be explored openly and safely."
The organization calls on Massachusetts voters to support Question 4, viewing it as a catalyst for broader discussions on psychedelic policy reform. Microdosing Collective remains committed to advocating for policies that recognize the unique nature of microdosing and ensure safe, legal access for those who choose to explore this practice.
About Microdosing Collective
Microdosing Collective is the only non-profit educational organization in the United States dedicated to advancing the right to microdose. Founded in 2023, it focuses on establishing a legal framework for microdosing psychedelics, particularly psilocybin, as wellness supplements. The organization is committed to educating the public, supporting research, and advocating for policy changes to create a safer, more accessible microdosing landscape.
